<DOC>
	<DOCNO>NCT02447016</DOCNO>
	<brief_summary>The aim prospective , open label study check difference neuropsychiatric neurocognitive measurement among patient switch Atripla Eviplera among 40 patient .</brief_summary>
	<brief_title>Decrease Neuropsychiatric Side Effects After Switching From Atripla Eviplera</brief_title>
	<detailed_description>40 patient Atripla least 12 week undetectable HIV-1 viral load randomly assign one two group ratio 1:1 : half patient switch Eviplera half remain Atripla . Neuropsychiatric symptom evaluate use specific questionnaire ( anxiety depression scale , sleep quality scale , etc ) neurocognitive function assess use standard test ( Trail A B , memory test , etc ) . Patient satisfaction assess use visual analog scale . Treatment efficacy evaluate measure rate patient HIV vilral load 50 copies/mL .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Emtricitabine , Rilpivirine , Tenofovir Drug Combination</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Ability understand sign write informed consent form Receiving Atripla continuously &gt; 12 week precede screen visit Plasma HIV1 RNA level ( least two measurement ) &lt; 50 copies/mL &gt; 8 week prior screen visit screen visit Atripla Truvada + Efavirenz first antiretroviral regimen HIV1 RNA &gt; 50 copies/mL measure two consecutive time point first achieve HIV RNA &lt; 50 copies/mL Had genotype prior start study drug know resistance study drug Normal ECG Hepatic transaminase ( AST ALT ) &lt; 5 X upper limit normal ( ULN ) Total bilirubin &lt; 1.5 mg/dL eGFR &gt; 60 mL/min Neutrophil count &gt; 1000/mm3 , platelet &gt; 50,000/mm3 . Haemoglobin &gt; 8.5 g/dL Age &gt; 18 Males Females childbearing potential must agree utilize highly effective contraception method ( two separate form contraception , one must effective barrier method , nonheterosexually active , practice sexual abstinence , vasectomized partner ) screen throughout duration study period 60 day follow last dose study drug . Subjects know allergy one study drug AIDS define event diagnose within 21 day prior screen Females pregnant breast feed Acute hepatitis diagnose within 21 day prior screen Subjects receive drug treatment HCV subject anticipate receive treatment HCV course study Implanted defibrillator pacemaker Current alcohol drug abuse judge investigator potentially interfere subject adherence Participation another interventional trial Ongoing therapy anticipate need initiate drug study contraindicate recommend use study drug ( Carbamazepine , Dexamethasone , Esomeprazole , Fosphenytoin , Lansoprazole , Omeprazole , Oxcarbazepine , Pantoprazole , Phenobarbital , Phenytoin , Piperaquine , Primnidone , Rabeprazole , Rifabutin , Rifampin , Rifapentine , St John 's Wort Any Severe Psychiatric disease judge investigator potentially interfere subject adherence protocol drug may interfere study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>